TipRanks
Can-Fite BioPharma (CANF)
:CANF
US Market
CANF
Can-Fite BioPharma
RESEARCH TOOLSreports
Want to see CANF full AI Analyst Report?

Can-Fite BioPharma (CANF) Stock News & Sentiment

660 Followers
Can-Fite Buy Rating Reaffirmed as Clinical Momentum Builds and $8 Price Target Remains Unchanged
Premium
Ratings
Can-Fite Buy Rating Reaffirmed as Clinical Momentum Builds and $8 Price Target Remains Unchanged
9d ago
CANF
Can-Fite Case Report Shows Namodenoson Bridged Decompensated Cirrhosis Patient to Liver Transplant
Premium
Company Announcements
Can-Fite Case Report Shows Namodenoson Bridged Decompensated Cirrhosis Patient to Liver Transplant
29d ago
6K
CANF
Can-Fite BioPharma Reports Mid-2026 Results and Updates Drug Development Programs
Premium
Company Announcements
Can-Fite BioPharma Reports Mid-2026 Results and Updates Drug Development Programs
30d ago
6K
CANF
Can-Fite BioPharma Cuts Warrant Exercise Price to Secure $4 Million Inducement Financing
Premium
Company Announcements
Can-Fite BioPharma Cuts Warrant Exercise Price to Secure $4 Million Inducement Financing
1M ago
6K
CANF
Can-Fite BioPharma Raises $4 Million Through Warrant Exercise to Fund Late-Stage Drug Pipeline
Premium
Company Announcements
Can-Fite BioPharma Raises $4 Million Through Warrant Exercise to Fund Late-Stage Drug Pipeline
1M ago
6K
CANF
Can-Fite Flags Longer Survival in Phase III Liver Cancer Trial, Eyes Earlier Interim Analysis
Premium
Company Announcements
Can-Fite Flags Longer Survival in Phase III Liver Cancer Trial, Eyes Earlier Interim Analysis
1M ago
6K
CANF
Can-Fite Reports New Data Supporting Namodenoson Combo Strategy in Pancreatic Cancer
Premium
Company Announcements
Can-Fite Reports New Data Supporting Namodenoson Combo Strategy in Pancreatic Cancer
2M ago
6K
CANF
More CANF News >

CANF News on the Web

Can-Fite BioPharma Cuts Warrant Exercise Price to Secure $4 Million Inducement Financing
TipRanks News
Neutral
Can-Fite reports longer-than-anticipated survival observed in Namodenoson study
TipRanks News
Bullish
Can-Fite BioPharma files $100M mixed securities shelf
TipRanks News
Bullish
Can-Fite BioPharma Advances Phase III Drug Candidates With Strengthened FDA and EMA Pathways
TipRanks News
Neutral
Can-Fite’s Namodenoson Pancreatic Cancer Data Accepted for ESMO 2026 Presentation
TipRanks News
Neutral
Can-Fite BioPharma Wins Australian Patent Backing Namodenoson in Liver and Pancreatic Cancer
TipRanks News
Neutral
Can-Fite BioPharma secures Australian Patent Office allowance for namodenoson
TipRanks News
Bullish
Can-Fite Completes Key Phase 3 Psoriasis Enrolment Milestone for Piclidenoson
TipRanks News
Neutral

News Score - Last 7 Days

Not enough data to generate a sentiment score
Media Buzz
This Week0 articles
Weekly Average0.75 articles
News Sentiment
Currently, no data available
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is CANF’s Media Buzz Sentiment?
Currently, no data Available
What is CANF’s weekly average amount of articles?
In an average week, 0.75 articles about CANF are published.
    What is CANF’s News Sentiment?
    Currently, no data Available
    Healthcare Stocks that are Trending in the News
    XENEXenon
    ABTAbbott Laboratories
    BBIOBridgeBio Pharma
    BDXBecton Dickinson
    NVSNovartis
    Showing the stocks with the most bullish news sentiment over the past week